市场调查报告书
商品编码
1601596
胞磷胆碱的全球市场:产品·用途·年龄层·流通管道·不同地区的预测 (~2032年)Global Citicoline Market Research Report Information by Product by Application, by Age Group by Distribution Channel, by Region Forecast till 2032 |
胞二磷胆碱市场规模将从2023年的4.3亿美元和2024年的4.8亿美元增长到2032年的10.4亿美元,预计在预测期内复合年增长率将达到8.99%。
由于健身和运动领域的需求不断增加、认知健康意识的增强以及世界各地对脸部美容的渴望不断增长,市场正在不断扩大。
人口老化、认知增强的需求、神经系统疾病的增加是推动市场扩张的主要因素。近年来,大众对在整个生命週期中维持大脑健康和认知功能重要性的理解发生了显着变化。推动这一变化的因素有很多,包括资讯可用性的增加、老年人口的增加以及对认知能力下降和阿兹海默症等神经系统疾病的日益担忧。
区域展望
2022年北美地区占最大市场占有率。这是由于北美老年人口不断增加,脸部矫正和增强手术越来越普遍,人均可支配收入明显更高。
由于该地区完善的製药和医疗基础设施以及人口老化,欧洲也占据第二大市场占有率。西班牙预计将在欧洲地区成长最快,而德国预计将拥有最大的市场占有率。
从 2024 年到 2032 年,亚太地区预计将大幅扩张。这是亚太地区对认知健康越来越了解并了解胞二磷胆碱补充剂可以提供的好处的结果。印度预计将成为该地区成长最快的国家,而中国预计将占据最大的市场占有率。
本报告提供全球胞磷胆碱的市场调查,彙整市场定义和概要,市场成长的各种影响因素分析,市场规模的转变·预测,各种区分·地区/各主要国家的明细,竞争环境,主要企业简介等资讯。
Global Citicoline Market Research Report Information by Product (Capsules, Tablets, Powder, Eye Drops, and Injection) by Application (Sports Nutrition, Personal Wellness, Treatment [Glaucoma, Stroke, Alzheimer disease, Channel (pression, and Others]), by Age Group (Pediatric, Adult, and Geriatric) by Distribution Channel (Online Channel, Offline Channel), by Region (North America, Europe, Asia-Pacific, and Rest of the World) Forecast till 2032
The size of the Citicoline market was estimated at USD 0.43 billion in 2023 and is expected to increase at a compound annual growth rate (CAGR) of 8.99% from 2024 to 2032, from USD 0.48 billion in 2024 to USD 1.04 billion by 2032. The market is expanding due to the growing demand from the fitness and sports sectors, the growing awareness of cognitive health, and the growing desire for facial aesthetics worldwide.
According to the report, the aging population, the need for cognitive enhancement, and the rise in neurological illnesses are the primary drivers of the market's expansion. The public's understanding of the significance of preserving brain health and cognitive function throughout life has significantly changed in recent years. Numerous variables, such as increased information availability, an older population, and growing worries about cognitive decline and neurological disorders like Alzheimer's, are to blame for this change.
Market Segments Insights
Type-wise, the Citicoline market is divided into capsules, tablets, powder, eye drops, and injections.
Sports nutrition, personal wellbeing, and treatment are among the applications that form the basis of the market segmentation. Treatment is further divided into categories such as bipolar depression, Alzheimer's illness, stroke, and glaucoma.
The market for Citicoline is segmented by age group, including geriatric, adult, and Pediatric.
The distribution channel, which encompasses both online and offline channels, provides the basis for market segmentation.
Regional Perspectives
In 2022, the biggest market share was held by the North American citicoline market. This is because the North American region's senior population is growing, facial correction and improvement surgeries are becoming more common, and per capita disposable income is considerable.
Due to a robust pharmaceutical and healthcare infrastructure, as well as an aging population throughout the region, the European citicoline market holds the second-largest market share. Furthermore, the Spanish citicoline market is anticipated to develop at the fastest rate in the European region, while the German citicoline market was said to have the greatest market share.
From 2024 to 2032, the Asia-Pacific citicoline market is anticipated to expand at a substantial rate. This is a result of the Asia-Pacific region's growing knowledge of cognitive health and the possible advantages of citicoline supplementation. Furthermore, the Asia-Pacific citicoline market is anticipated to grow at the fastest rate in India, while the China market is predicted to hold the greatest market share.
Africa, Latin America, and the Middle East make up the rest of the world. A increasing senior population and more awareness of cognitive health are expected to fuel growth in the aforementioned regions' citicoline markets.
Companies like Invision Medi Sciences (India), RPG Life Sciences Ltd (India), CHEMO BIOLOGICAL (India), Century Pharma (India), HARBIN PHARMACEUTICAL GROUP (China), UNION KOREA PHARM CO LTD (South Korea), Kyowa Hakko Bio Co., Ltd (Japan), Vitabiotics Ltd (UK), Grupo Ferrer Internacional, S.A (Spain), and Life Extension (US) are just a few examples.